Q1 Earnings Forecast for OmniAb Issued By HC Wainwright

OmniAb, Inc. (NASDAQ:OABI) – Stock analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of OmniAb in a report issued on Thursday, March 5th. HC Wainwright analyst J. Pantginis expects that the company will post earnings of ($0.09) per share for the quarter. The consensus estimate for OmniAb’s current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for OmniAb’s FY2026 earnings at ($0.36) EPS, FY2027 earnings at ($0.25) EPS, FY2028 earnings at ($0.11) EPS and FY2029 earnings at ($0.06) EPS.

OmniAb (NASDAQ:OABI) last issued its earnings results on Wednesday, March 4th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.03). OmniAb had a negative net margin of 347.04% and a negative return on equity of 23.99%. The company had revenue of $8.38 million for the quarter, compared to analysts’ expectations of $9.00 million.

A number of other brokerages also recently issued reports on OABI. Benchmark reissued a “buy” rating on shares of OmniAb in a research report on Friday. Wall Street Zen raised shares of OmniAb from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OmniAb in a research note on Monday, December 22nd. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.67.

OmniAb Price Performance

NASDAQ OABI opened at $1.89 on Monday. The stock has a market capitalization of $272.08 million, a PE ratio of -3.32 and a beta of 0.13. OmniAb has a 1 year low of $1.22 and a 1 year high of $3.45. The business’s 50-day moving average is $1.83 and its 200 day moving average is $1.75.

Institutional Trading of OmniAb

Institutional investors and hedge funds have recently modified their holdings of the business. The Manufacturers Life Insurance Company raised its holdings in shares of OmniAb by 20.5% during the second quarter. The Manufacturers Life Insurance Company now owns 44,809 shares of the company’s stock valued at $78,000 after purchasing an additional 7,624 shares during the last quarter. Rhumbline Advisers boosted its holdings in OmniAb by 6.0% in the second quarter. Rhumbline Advisers now owns 160,728 shares of the company’s stock worth $280,000 after purchasing an additional 9,163 shares during the last quarter. Osaic Holdings Inc. grew its position in OmniAb by 214.4% in the 2nd quarter. Osaic Holdings Inc. now owns 14,247 shares of the company’s stock worth $25,000 after purchasing an additional 9,716 shares during the period. AQR Capital Management LLC bought a new stake in OmniAb in the 1st quarter worth approximately $25,000. Finally, BNP Paribas Financial Markets raised its stake in OmniAb by 92.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 21,721 shares of the company’s stock valued at $35,000 after buying an additional 10,438 shares during the last quarter. Institutional investors own 72.08% of the company’s stock.

Insider Buying and Selling at OmniAb

In other OmniAb news, CEO Matthew W. Foehr sold 30,843 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $1.71, for a total transaction of $52,741.53. Following the completion of the sale, the chief executive officer directly owned 4,403,277 shares in the company, valued at approximately $7,529,603.67. This trade represents a 0.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 84,389 shares of company stock worth $143,959 in the last ninety days. 8.60% of the stock is owned by company insiders.

About OmniAb

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.